Los Angeles Capital Management LLC Purchases New Stake in Aldeyra Therapeutics, Inc. $ALDX

Los Angeles Capital Management LLC purchased a new position in shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) in the second quarter, HoldingsChannel.com reports. The fund purchased 16,320 shares of the biotechnology company’s stock, valued at approximately $63,000.

Several other institutional investors have also added to or reduced their stakes in the company. CWM LLC lifted its position in shares of Aldeyra Therapeutics by 1,164.4% during the 1st quarter. CWM LLC now owns 19,244 shares of the biotechnology company’s stock worth $111,000 after buying an additional 17,722 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Aldeyra Therapeutics during the first quarter worth $134,000. Invesco Ltd. raised its position in Aldeyra Therapeutics by 1,575.7% in the first quarter. Invesco Ltd. now owns 501,137 shares of the biotechnology company’s stock valued at $2,882,000 after purchasing an additional 471,231 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Aldeyra Therapeutics during the first quarter worth about $155,000. Finally, Fox Run Management L.L.C. bought a new position in Aldeyra Therapeutics in the 1st quarter valued at approximately $132,000. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on ALDX. Zacks Research upgraded shares of Aldeyra Therapeutics to a “hold” rating in a report on Friday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aldeyra Therapeutics in a research report on Wednesday, October 8th. Finally, BTIG Research reiterated a “buy” rating and issued a $9.00 target price on shares of Aldeyra Therapeutics in a report on Monday, November 10th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $9.50.

Aldeyra Therapeutics Stock Down 0.8%

NASDAQ ALDX opened at $4.91 on Wednesday. Aldeyra Therapeutics, Inc. has a 52 week low of $1.14 and a 52 week high of $7.20. The business has a 50 day moving average price of $5.20 and a 200-day moving average price of $4.47. The company has a market cap of $295.40 million, a price-to-earnings ratio of -5.78 and a beta of 0.79.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.04. On average, equities research analysts anticipate that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.